--- title: "Evidence: universal antioxidant, glucose metabolism" description: "Oral alpha-lipoic acid may reduce sensory symptoms and improve global satisfaction in diabetic neuropathy patients, with higher doses showing a greater…" url: "https://magellanlongevity.com/study/s129.md" canonical: "https://magellanlongevity.com/study/s129.html" html: "https://magellanlongevity.com/study/s129.html" type: "study" study_key: "s129" journal: "Nutrients" year: 2023 pmid: "37630823" doi: "10.3390/nu15163634" citations: 1 updated: 2026-09-02 author: "Gabriel Radu, DO" author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765." publisher: "Magellan Longevity" content_format: "markdown" --- # Evidence: universal antioxidant, glucose metabolism [Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › Evidence: universal antioxidant, glucose metabolism **HTML version:** https://magellanlongevity.com/study/s129.html · **In the Magellan app:** https://magellanlongevity.com/#/study/s129 ## Citation | Field | Value | | --- | --- | | Journal | Nutrients | | Year | 2023 | | PMID | [37630823](https://pubmed.ncbi.nlm.nih.gov/37630823/) | | DOI | [10.3390/nu15163634](https://doi.org/10.3390/nu15163634) | | Study key | s129 | ## Takeaway Oral alpha-lipoic acid may reduce sensory symptoms and improve global satisfaction in diabetic neuropathy patients, with higher doses showing a greater effect on some outcomes. ## The question What are the effects of orally administered alpha-lipoic acid (ALA) compared to a placebo in patients with diabetic sensorimotor peripheral neuropathy (DSPN), and what is the optimal dosage? ## Hypothesis The researchers hypothesized that oral ALA would improve symptoms in DSPN patients by reducing oxidative stress and improving microcirculation, and they aimed to determine an optimal dosage. ## Methods A meta-analysis of ten randomized controlled trials (RCTs) involving 1242 patients was conducted. The studies were retrieved from PubMed, Embase, and Cochrane databases. Primary outcome was total symptoms' score (TSS), and secondary outcomes included neurological disability score (NDS), neuropathy impaired score (NIS), NIS-lower limb (NIS-LL), vibration perception threshold (VPT), nerve conduction study (NCS) results, and global satisfaction. A subgroup analysis was performed for ALA dosages of 600, 1200, and 1800 mg/day. ## Results ALA treatment showed favorable results for total symptoms' score (TSS), neurological disability score (NDS), and global satisfaction score. A dose-related trend was observed for TSS and global satisfaction. However, ALA did not produce favorable results for VAS, VPT, NIS-LL, and NCS results. ## Conclusion Oral ALA treatment has favorable effects on DSPN by reducing sensory symptoms, with a dose-dependent response observed for TSS and global satisfaction score. Further research is needed to investigate the use of ALA for preventing neurological symptoms. ## Limitations The abstract does not explicitly state limitations of the meta-analysis itself, but it suggests that further research is needed to investigate ALA's role in preventing neurological symptoms. ## Verbatim from the abstract > ALA treatment had favorable effects by reducing sensory symptoms ## Where this study is used on Magellan This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions. | Compound or device | Evidence grade | Graded pages | | --- | --- | --- | | Alpha-Lipoic Acid (ALA) | Moderate evidence | [Alpha-Lipoic Acid (ALA)](https://magellanlongevity.com/p/129.md) | ## Reference 1. **Evidence: universal antioxidant, glucose metabolism** Nutrients 2023 · [PMID 37630823](https://pubmed.ncbi.nlm.nih.gov/37630823/) · [DOI 10.3390/nu15163634](https://doi.org/10.3390/nu15163634) > ALA treatment had favorable effects by reducing sensory symptoms ## Structured data ```json {"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/s129.html#page","url":"https://magellanlongevity.com/study/s129.html","name":"Evidence: universal antioxidant, glucose metabolism","description":"Oral alpha-lipoic acid may reduce sensory symptoms and improve global satisfaction in diabetic neuropathy patients, with higher doses showing a greater…","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/s129.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"Evidence: universal antioxidant, glucose metabolism","item":"https://magellanlongevity.com/study/s129.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/s129.html#study","name":"Evidence: universal antioxidant, glucose metabolism","headline":"Evidence: universal antioxidant, glucose metabolism","datePublished":"2023","isPartOf":{"@type":"Periodical","name":"Nutrients"},"identifier":"PMID:37630823","url":"https://pubmed.ncbi.nlm.nih.gov/37630823/","sameAs":"https://doi.org/10.3390/nu15163634","abstract":"Oral alpha-lipoic acid may reduce sensory symptoms and improve global satisfaction in diabetic neuropathy patients, with higher doses showing a greater effect on some outcomes."}]} ``` ## Related on Magellan Longevity - [Alpha-Lipoic Acid (ALA)](https://magellanlongevity.com/p/129.md) — product graded on this and related evidence - [Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A…](https://magellanlongevity.com/study/d32370731.md) - [Examining oxidative stress as a mechanistic link between sleep irregularity and…](https://magellanlongevity.com/study/ala_redox.md) - [Longevity research map](https://magellanlongevity.com/longevity-research-map.html) - [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md) ## Scope and disclosures Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication. Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases. Reviewed for accuracy by a board-certified physician (DO).